Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The artificial pancreas.

Paolo Brunetti1, Marco Orsini Federici, Massimo Massi Benedetti

  • 1Dipartimento di Medicina Interna, Università di Perugia, Perugia, Italy. brunetti@dimisen.med.unipg.it

Artificial Cells, Blood Substitutes, and Immobilization Biotechnology
|May 20, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FAIR foundations of a novel indicator vault for non-communicable diseases in the European Union: feasibility study for effective contextualisation of indicators.

Frontiers in digital health·2026
Same author

A taxonomy of indicators for non-communicable diseases: agreement, definition, and contextual description using diabetes as a case study.

Frontiers in public health·2025
Same author

Real-world data and patient-reported outcomes in diabetes in Emilia-Romagna (REWINDER): protocol of a federated cohort study for the regional evaluation of quality of care during and after COVID-19.

BMJ open·2025
Same author

Improving outcomes with early and intensive metabolic control in patients with type 2 diabetes: a long-term modeling analysis of clinical and cost outcomes in Italy.

Journal of diabetes and metabolic disorders·2025
Same author

The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.

Journal of medical economics·2024
Same author

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.

Diabetes, obesity & metabolism·2023
Same journal

The effect of polymerized placenta hemoglobin on renal ischemia/reperfusion injury.

Artificial cells, blood substitutes, and immobilization biotechnology·2012
Same journal

Immune-stimulating potential of cell envelope proteins from Vibrio cholerae associated to chitosan microparticles: an in vitro study.

Artificial cells, blood substitutes, and immobilization biotechnology·2012
Same journal

Immobilization of anti-aflatoxin B1 antibody by UV polymerization of aniline and aflatoxin B1 detection via electrochemical impedance spectroscopy.

Artificial cells, blood substitutes, and immobilization biotechnology·2012
Same journal

Purification and characterization of prophenoloxidase from Galleria mellonella L.

Artificial cells, blood substitutes, and immobilization biotechnology·2012
Same journal

Chitosan-based intragastric delivery of cefuroxime axetil: development and in-vitro evaluation of mucoadhesive approach.

Artificial cells, blood substitutes, and immobilization biotechnology·2012
Same journal

In vitro effect of novel β-lactam compounds on xanthine oxidase enzyme activity.

Artificial cells, blood substitutes, and immobilization biotechnology·2012
See all related articles

Type 1 diabetes management requires insulin therapy. An artificial pancreas aims for physiological insulin replacement, but reliable continuous glucose monitoring and control algorithms remain key challenges for this wearable technology.

Area of Science:

  • Biomedical Engineering
  • Endocrinology
  • Diabetes Technology

Background:

  • Type 1 diabetes necessitates exogenous insulin due to absolute insulin deficiency.
  • Insulin therapy is crucial for preventing ketoacidotic coma and chronic diabetes complications.
  • Physiological insulin replacement therapy is an ongoing goal in diabetes management.

Purpose of the Study:

  • To review the development and essential components of the artificial pancreas.
  • To identify current challenges and future directions in artificial pancreas technology.
  • To discuss the integration of continuous glucose monitoring with insulin delivery systems.

Main Methods:

  • Review of historical and current approaches to artificial pancreas development.
  • Identification of four essential components: sampling system, glucose sensor, mathematical models/algorithms, and infusion system.

Related Experiment Videos

  • Analysis of technological advancements and remaining obstacles.

    • Main Results:

    • The artificial pancreas integrates continuous glucose monitoring with automated insulin delivery.
    • Key components include sensors, algorithms for dose calculation, and insulin infusion systems.
    • Miniaturization technologies are advancing, but reliable continuous glucose monitors and control algorithms are still needed.

    Conclusions:

    • The artificial pancreas represents a significant advancement towards physiological insulin replacement.
    • Reliable continuous glucose monitoring and sophisticated control algorithms are critical for effective artificial pancreas function.
    • Further research and technological development are necessary to overcome current limitations and realize the full potential of wearable artificial pancreas systems.